PR
Prostatype Genomics AB (publ)
PROGEN.ST · STO
0.17 kr +0.00% (+0.00 kr)
1M +72.76%
Market Cap 5.61M kr
P/E Ratio -
Div. Yield -
ROE 185.25%
Bulios Fair Price
0.19 kr
11.8% upside
Current Price
0.17 kr
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PROGEN.ST is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
50 /100
Fair P/S 9.44x
P/B 0.21x
P/E N/A
Growth
6 /100
Declining Rev. growth 4.55%
Book val. growth 0.48%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 6,332.66%
FCF margin 4,050.34%
Net margin 7,492.09%
Quality
0 /100
Poor ROIC 147.32%
Asset turnover 0.01x
ROE 185.25%
Debt
47 /100
Moderate Debt/Equity 0.00x
Int. coverage -24.20x
Current ratio 0.44x
Stability
13 /100
Unstable Beta 1.41x
Profitable years 0
Rev. volatility 143.96%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PROGEN.ST
Online
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Fredrik Rickman
Employees
7
Headquarters
Nacka Strand